|
Histamine
|
DB05381 |
[A depressor amine derived by enzymatic decarboxylation of histidine. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter.] |
|
N-Propyl Isocyanide
|
DB04050 |
|
|
DOTMP HO-166
|
DB05380 |
[DOTMP HO-166 is used in skeletal targeted radiotherapy (STR). SRT is designed to be used in combination with high-dose chemotherapy producing a direct therapeutic effect on the tumor sites in the bone plus a general bone-marrow effect to destroy myeloma cells in the bone marrow. It is an experimental therapy that is being developed by NeoRx Corporation.] |
|
8-(Pyrimidin-2-Ylamino)Naphthalene-2-Carboximidamide
|
DB04059 |
|
|
Tetrachlorodecaoxide
|
DB05389 |
[WF10 is a chlorite-based, immunomodulating drug is developed by Nuvo Research Inc. Certain preclinical evidence and clinical pilot data suggest that WF10 may be effective in treating certain cancers. The Corporation believes the research to-date demonstrates that WF10 acts on macrophages (a type of white blood cell) by modulating the balance between inflammation and phagocytosis, a state in which the body digests foreign, potentially harmful substances. The Corporation has commenced a Phase II clinical trial in an effort to demonstrate the efficacy of WF10 in combination with Xeloda (capecitabine) in the treatment of pancreatic cancer. The trial is being conducted in Germany at the University of Heidelberg and the National Centre for Tumor Diseases.] |
|
Beta-Dadf, Msa, Multisubstrate Adduct Inhibitor
|
DB04057 |
|
|
D-[(Amino)Carbonyl]Phenylalanine
|
DB04058 |
|
|
para-Coumaric Acid
|
DB04066 |
|
|
C31G
|
DB05398 |
[C31G is a potent broad spectrum antimicrobial agent, effective against gram positive and gram negative bacteria, yeast and fungi.C31G, vaginal gel is developed by Biosyn Inc. and has commenced enrollment in a phase III pivotal clinical trial for the reduction of sexual transmission of human immunodeficiency virus (HIV).] |
|
4-hydroxybenzyl coenzyme A
|
DB04067 |
|
|
Albinterferon Alfa-2B
|
DB05396 |
[Albumin-interferon alpha (Albuferon) is a novel, long-acting form of interferon alpha. Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B, and a broad range of cancers. Human Genome Sciences modified interferon alpha to improve its pharmacological properties by using the company's proprietary albumin fusion technology. Human Genome Sciences is developing Albuferon as a potential treatment for chronic hepatitis C. The drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C. In response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they ceased development of the drug.] |
|
Nogalaviketone
|
DB04064 |
|
|
N-Cyclopentyl-N-Cyclobutylformamide
|
DB04065 |
|
|
Amibegron
|
DB05395 |
[Amibegron is an agonist for atypical beta3-adrenoceptors which inhibits intestinal motility.] |
|
Corticorelin
|
DB05394 |
[Corticotropin-releasing factor is studied in the treatment of brain cancer. It is made naturally by the hypothalamus (a part of the brain) and can also be made in the laboratory. Human corticotropin-releasing factor may help reduce symptoms caused by edema (swelling) of the brain. It is a type of neurohormone, also called hCRF.] |
|
Beta-D-Fucose
|
DB04062 |
|
|
2-Methylleucine
|
DB04063 |
|
|
NOV-002
|
DB05393 |
[NOV-002, the lead compound acts as a chemoprotectant and an immunomodulator, in combination with chemotherapy. NOV-002 is approved and marketed in the Russian Fereration by Pharma BAM under the trade name Glutoxim. It has been administered to over 10,000 patients, demonstrating clinical efficacy and excellent safety data.] |
|
(5-Methyl-6-Oxo-1,6-Dihydro-Pyridin-3-Yl)-1,2-Dideoxy-Ribofuranose-5-Monophosphate
|
DB04060 |
|
|
Alpha-Amino-2-Indanacetic Acid
|
DB04061 |
|
